JPMorgan Chase & Co. Sells 28,073 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

JPMorgan Chase & Co. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,166 shares of the company’s stock after selling 28,073 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.47% of Medpace worth $48,893,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Pallas Capital Advisors LLC grew its holdings in shares of Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Barclays PLC grew its holdings in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC increased its position in Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after acquiring an additional 844 shares during the period. Janus Henderson Group PLC raised its stake in shares of Medpace by 10.0% during the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock valued at $14,722,000 after acquiring an additional 4,023 shares during the last quarter. Finally, SYM FINANCIAL Corp acquired a new position in shares of Medpace during the fourth quarter worth $320,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP stock opened at $287.11 on Friday. The stock’s 50 day simple moving average is $331.56 and its 200 day simple moving average is $337.49. The company has a market cap of $8.75 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a fifty-two week low of $282.42 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on MEDP shares. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Finally, Leerink Partners initiated coverage on Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective on the stock. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.